Oncologic Outcomes Following Three Different Approaches to the Distal Ureter and Bladder Cuff in Nephroureterectomy for Primary Upper Urinary Tract Urothelial Carcinoma

Comparison of Efficacy of Adjuvant MEC (Methotrexate, Epirubicin and Cisplatin) and GC (Gemcitabine and Cisplatin) in Advanced Upper Tract Urothelial Carcinoma

“…Its behavior appears multi-focal and in 17% of cases, concurrent bladder cancer is present (4). Furthermore, an estimated 22-47% of patients with UTUC may suffer from bladder recurrence (5) and 2-6% of patients suffer from contralateral recurrence (6).…”

Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma

“…In a retrospective series of 301 patients who underwent nephroureterectomy, Li and colleagues reported 5-year recurrence-free survival for patients with pTa/pTis/pT1, pT2, pT3, and pT4 tumours of 76.6%, 65.4%, 41.2%, and 0%, respectively. 16 In a large retrospective multicentre series of 1363 patients, Margulis and colleagues reported 5-year extravesical recurrence-free survival for pTa/pTis, pT1, pT2, pT3, and pT4 tumours of 91.8%, 88%, 71%, 48%, and 4.7%, respectively. 19 Additionally, tumour grade is associated with oncologic outcomes.…”

“…31 Other prognostic variables following nephroureterectomy include lymphovascular invasion, concomitant carcinoma in situ (CIS), positive surgical margins, ureteral tumour location (as opposed to renal pelvis), previous or concomitant bladder tumours, tumour multifocality, and lack of postoperative intravesical mitomycin C instillation. 4,6,7,[10][11][12][14][15][16][17][18][19][21][22][23][24]26,[28][29][30][31][32][33][34][35][36][65][66][67][68][69] The rates of recurrence stratified by these variables are seldom reported.…”

Vinflunine in the Τreatment of Upper Tract Urothelial Carcinoma – Subgroup Analysis of an Observational Study

“…Liver metastases, representing a negative prognostic factor, were counted in 22.4% (UTUC) vs. 8.4% (UCB) of patients (9,10). Furthermore, disease recurrence rates in UTUC patients were reported to be 22-47% in the bladder (11,12) and 2-6% in the contralateral upper tract (13,14). Localized in the upper urinary tract, these tumors hamper adequate tissue sampling under ureteroscopy and impede proper clinical staging (15).…”